Pfizer came up with some solidly positive Phase II data for a new drug that’s designed to throw a monkey wrench into the biology driving the hedgehog pathway in acute myeloid leukemia.
Investigators said that glasdegib, an oral SMO inhibitor initially coded PF-04449913, significantly increased the overall survival of a group of patients taking the drug in combination with low-dose cytarabine (LDAC) compared to LDAC alone.
The median OS for the combo drug arm was 8.8 months compared to only 4.9 months for LDAC as a monotherapy, the pharma giant noted at the big ASH ’16 gathering in San Diego.
Mace Rothenberg, MD, chief development officer, Oncology, Pfizer Global Product Development, had this to say:
“Acute myeloid leukemia is a rapidly progressing blood cancer for which new treatment options are needed. Pfizer is excited about the promising data seen in AML patients treated with glasdegib and is working to explore further opportunities to evaluate glasdegib in the treatment of this disease.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,500+ biopharma pros who read Endpoints News by email every day.Free Subscription